The prognostic significance of tumor-infiltrating lymphocytes assessment with hematoxylin and eosin sections in resected primary lung adenocarcinoma.
Adenocarcinoma of Lung
/ mortality
Adult
Aged
Aged, 80 and over
Coloring Agents
/ chemistry
Eosine Yellowish-(YS)
/ chemistry
Female
Hematoxylin
/ chemistry
Humans
Lung
/ cytology
Lung Neoplasms
/ mortality
Lymphocytes, Tumor-Infiltrating
/ pathology
Male
Middle Aged
Neoplasm Staging
Pneumonectomy
Prognosis
Progression-Free Survival
Retrospective Studies
Staining and Labeling
/ methods
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
07
04
2019
accepted:
15
10
2019
entrez:
20
11
2019
pubmed:
20
11
2019
medline:
3
4
2020
Statut:
epublish
Résumé
The prognostic significance of tumor-infiltrating lymphocytes has been determined in cancers of the lung, colon and breast, though there is no standardized method for using this prognostic indicator for lung cancer. We applied a modified version of the method proposed by the International Immuno-Oncology Biomarkers Working Group to primary lung adenocarcinoma, which uses histologic findings of hematoxylin and eosin sections. The study included a total cohort of 146 lung adenocarcinoma patients who underwent lobectomy with lymph node dissection at two hospitals between 2008 and 2012. The full-face sections of hematoxylin and eosin-stained slides were reviewed, and we evaluated the level of tumor-infiltrating lymphocytes as a percentage of the area occupied out of the total intra-tumoral stromal area. Histopathologic factors include histologic grade, necrosis, extracellular mucin, lymphovascular invasion, lymph node metastasis, level of tumor infiltrating lymphocytes, tertiary lymphoid structures around the tumor, and the presence of a germinal center in tertiary lymphoid structures. The high level of tumor-infiltrating lymphocytes was found to be significantly correlated with the histologic grade (p = 0.023), necrosis (p = 0.042), abundance of tertiary lymphoid structures(p<0.001) and presence of a germinal center in tertiary lymphoid structures (p = 0.004). A high level of tumor-infiltrating lymphocytes was associated with better progression-free survival (p = 0.011) as well as overall survival (p = 0.049). On multivariable analysis, high tumor-infiltrating lymphocyte levels were a good independent prognostic factor for progression-free survival (Hazard ratio: 0.389, 95% confidence interval: 0.161-0.941, p = 0.036). Histologic evaluation of tumor-infiltrating lymphocytes level in lung adenocarcinoma with H&E sections therefore has prognostic value in routine surgical pathology.
Identifiants
pubmed: 31743333
doi: 10.1371/journal.pone.0224430
pii: PONE-D-19-09876
pmc: PMC6863614
doi:
Substances chimiques
Coloring Agents
0
Eosine Yellowish-(YS)
TDQ283MPCW
Hematoxylin
YKM8PY2Z55
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0224430Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
J Clin Oncol. 2008 Sep 20;26(27):4410-7
pubmed: 18802153
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Cancer Res Treat. 2017 Apr;49(2):313-321
pubmed: 27456948
J Surg Res. 2011 Nov;171(1):1-5
pubmed: 21571304
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Cancer Res. 2014 Feb 1;74(3):705-15
pubmed: 24366885
Cell Physiol Biochem. 2015;37(4):1560-71
pubmed: 26513143
Lung Cancer. 2013 Sep;81(3):371-376
pubmed: 23891509
Oncotarget. 2016 Feb 9;7(6):7227-40
pubmed: 26811495
Front Immunol. 2016 Jun 30;7:258
pubmed: 27446088
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Pathobiology. 2000 Jan-Feb;68(1):1-8
pubmed: 10859525
Curr Opin Oncol. 1992 Apr;4(2):323-33
pubmed: 1591305
Clin Cancer Res. 2008 Aug 15;14(16):5220-7
pubmed: 18698040
Hum Pathol. 2018 Sep;79:188-198
pubmed: 29885403
Histopathology. 2009 Sep;55(3):301-12
pubmed: 19723145
J Immunol. 2015 Apr 1;194(7):3475-86
pubmed: 25725111
Scand J Immunol. 1998 Feb;47(2):159-62
pubmed: 9496692
J Surg Res. 2011 May 15;167(2):207-10
pubmed: 19896677
J Immunol. 2004 Apr 15;172(8):4844-50
pubmed: 15067062
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
J Clin Oncol. 2013 Feb 1;31(4):490-8
pubmed: 23269987
JAMA. 2011 Nov 2;306(17):1891-901
pubmed: 22045767
Proc Am Thorac Soc. 2011 Sep;8(5):381-5
pubmed: 21926387
Thorax. 1993 Nov;48(11):1130-4
pubmed: 8296257
Clin Cancer Res. 2015 Jun 1;21(11):2635-43
pubmed: 25680376
J Clin Oncol. 2016 Apr 10;34(11):1223-30
pubmed: 26834066